Interaction between flucloxacillin and azoles: Is isavuconazole next? - PubMed (original) (raw)

. 2021 Dec;64(12):1508-1511.

doi: 10.1111/myc.13373. Epub 2021 Oct 9.

Affiliations

• PMID: 34553797
• DOI: 10.1111/myc.13373

Interaction between flucloxacillin and azoles: Is isavuconazole next?

Ruth Van Daele et al. Mycoses. 2021 Dec.

Abstract

Background: Isavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. It has been previously reported that an interaction between flucloxacillin and voriconazole may lead to subtherapeutic voriconazole exposure, when used concomitantly. Since isavuconazole is also metabolised via cytochrome P450 enzymes, the same interaction may be expected.

Objectives: We aim to document exposure to isavuconazole in patients concomitantly treated with flucloxacillin.

Patients: We report two patients treated with both isavuconazole and flucloxacillin, in whom we determined isavuconazole concentrations.

Results: Low isavuconazole trough concentrations (<1 mg/L) were observed in two patients under concomitant treatment with flucloxacillin.

Conclusions: In combination with flucloxacillin, low isavuconazole concentrations were observed but an adequate isavuconazole exposure may be reached with dose augmentation. Therapeutic drug monitoring of isavuconazole is recommended to ensure an adequate exposure.

Keywords: CYP450; azoles; drug-drug interaction; flucloxacillin; isavuconazole.

© 2021 Wiley-VCH GmbH.

PubMed Disclaimer

Similar articles

• Broad-spectrum azoles and flucloxacillin: a dangerous match.
  Vangheluwe T, Van Hoecke F, Dumoulin A, Vogelaers D. Vangheluwe T, et al. Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):153-154. doi: 10.1007/s10096-021-04333-z. Epub 2021 Sep 7. Eur J Clin Microbiol Infect Dis. 2022. PMID: 34494173 Free PMC article.
• Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
  Denis J, Ledoux MP, Nivoix Y, Herbrecht R. Denis J, et al. J Mycol Med. 2018 Mar;28(1):8-14. doi: 10.1016/j.mycmed.2018.02.005. Epub 2018 Mar 11. J Mycol Med. 2018. PMID: 29534853 Review.
• Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
  Shirley M, Scott LJ. Shirley M, et al. Drugs. 2016 Nov;76(17):1647-1657. doi: 10.1007/s40265-016-0652-6. Drugs. 2016. PMID: 27766566 Review.
• Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
  Murrell D, Bossaer JB, Carico R, Harirforoosh S, Cluck D. Murrell D, et al. Int J Pharm Pract. 2017 Feb;25(1):18-30. doi: 10.1111/ijpp.12302. Epub 2016 Aug 29. Int J Pharm Pract. 2017. PMID: 27569742 Review.
• Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
  Sanglard D, Coste AT. Sanglard D, et al. Antimicrob Agents Chemother. 2015 Oct 19;60(1):229-38. doi: 10.1128/AAC.02157-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26482310 Free PMC article.

Cited by

• The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review.
  Cattaneo D, Gervasoni C, Corona A. Cattaneo D, et al. Antibiotics (Basel). 2022 Oct 13;11(10):1410. doi: 10.3390/antibiotics11101410. Antibiotics (Basel). 2022. PMID: 36290068 Free PMC article. Review.
• Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.
  Armengol Álvarez L, Van de Sijpe G, Desmet S, Metsemakers WJ, Spriet I, Allegaert K, Rozenski J. Armengol Álvarez L, et al. Antibiotics (Basel). 2022 May 21;11(5):701. doi: 10.3390/antibiotics11050701. Antibiotics (Basel). 2022. PMID: 35625345 Free PMC article. Review.
• A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.
  Thompson GR 3rd, Chen SC, Alfouzan WA, Izumikawa K, Colombo AL, Maertens J. Thompson GR 3rd, et al. Med Mycol. 2024 Sep 6;62(9):myae083. doi: 10.1093/mmy/myae083. Med Mycol. 2024. PMID: 39138063 Free PMC article. Review.

References

REFERENCES

1. 1. Pfizer Summary of Product Characteristics (SmPC) Cresemba.https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product...
2. 1. Kennedy B, Larcombe R, Chaptini C, Gordon DL. Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection. J Antimicrob Chemother. 2015;70:2171-2173.
3. 1. Muilwijk EW, Dekkers BGJ, Henriet SSV, et al. Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrob Agents Chemother. 2017;61(9):e00915-e00917.
4. 1. Veenhof H, Schouw HM, Besouw MTP, Touw DJ, Gracchi V. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study. Eur J Clin Pharmacol. 2020;76(12):1667-1673.
5. 1. Du QQ, Wang ZJ, He L, Jiang XH, Wang L. PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69(11):1917-1925.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley